These monoclonal antibodies target specific immune checkpoints, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), thereby potentiating immune responses against cancer cells. The gene discussed is PDCD1; the disease is cancer.